CDA’s recommendation for lecanemab funding
The Agency has recommended against public reimbursement for the disease-modifying therapy.
Canada’s Drug Agency, which evaluates clinical evidence, safety, cost effectiveness and system readiness to guide provincial and territorial public funding decisions, has released a draft recommendation against public reimbursement for lecanemab.
Lecanemab is a new disease-modifying therapy for early-stage Alzheimer’s disease that was conditionally approved by Health Canada in the fall.
This draft recommendation is discouraging for many people living with dementia and their families. However, the Agency’s decision remains open for feedback until March 5, when a final recommendation will be made.
We share the disappointment surrounding this draft recommendation. At the same time, it underscores the need to address health-care system capacity and existing inequities, so we can be prepared to deliver treatments more effectively, accessibly, and fairly.
The Agency identified several systemic and equity considerations in its decision, including the need for improved access to timely diagnosis and clearer care pathways — particularly for individuals who face barriers accessing health care due to geography, gender or identity. The draft recommendation also noted uncertainty regarding the therapy’s benefits and safety.
The Alzheimer Society of Manitoba remains committed to representing the voices of people living with dementia and care partners, and to advocating for equitable access to care, supports and emerging treatment options.